investor.sophirisbio.com

Sophiris Bio Inc. - Investor Relations

Prostate cancer program overview. Events & presentations. 01/12/17 4:00 PM ET. Pricing provided by eSignal. Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference. Nov 22, 2016. Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights. Nov 9, 2016. Download the Sophiris Investor Presentation. 28th Annual Piper Jaffray Healthcare Conference. Nov 30, 2016 at 9:30 AM ET. 2016 BIO Investor Forum. Oct 18, 2016 at 10:30 AM PT.

http://investor.sophirisbio.com/

OVERVIEW OF investor.sophirisbio.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

13

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.SOPHIRISBIO.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

February

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Monday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.4 out of 5 with 9 reviews

5 star

6

4 star

1

3 star

2

2 star

0

1 star

0

Hey there! Start your review of investor.sophirisbio.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.7 seconds

FAVICON PREVIEW

16x16

CONTACTS AT INVESTOR.SOPHIRISBIO.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

13

SSL

EXTERNAL LINKS

45

SITE IP

206.200.251.19

LOAD TIME

0.687 sec

SCORE

6.2

PAGE TITLE

Sophiris Bio Inc. - Investor Relations | investor.sophirisbio.com Reviews

<META> DESCRIPTION

Prostate cancer program overview. Events & presentations. 01/12/17 4:00 PM ET. Pricing provided by eSignal. Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference. Nov 22, 2016. Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights. Nov 9, 2016. Download the Sophiris Investor Presentation. 28th Annual Piper Jaffray Healthcare Conference. Nov 30, 2016 at 9:30 AM ET. 2016 BIO Investor Forum. Oct 18, 2016 at 10:30 AM PT.

<META> KEYWORDS

1 Sophiris Bio

2 proteins

3 novel

4 targeted therapeutics

5 treatment

6 prostate diseases

7 PORxinï¿½

8 INxinï¿½

9 benign prostatic hyperplasia

10 BPH

CONTENT

Page content here

KEYWORDS ON PAGE

management,board of directors,bph program overview,clinical trials,publications,investor relations,news,corporate governance,financial information,stock information,contact investor relations,shareholder tools,nasdaq sphs,high,volume,market cap,view all

POWERED BY

ASP.NET

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Sophiris Bio Inc. - Investor Relations | investor.sophirisbio.com Reviews

https://investor.sophirisbio.com

Prostate cancer program overview. Events & presentations. 01/12/17 4:00 PM ET. Pricing provided by eSignal. Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference. Nov 22, 2016. Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights. Nov 9, 2016. Download the Sophiris Investor Presentation. 28th Annual Piper Jaffray Healthcare Conference. Nov 30, 2016 at 9:30 AM ET. 2016 BIO Investor Forum. Oct 18, 2016 at 10:30 AM PT.

INTERNAL PAGES

investor.sophirisbio.com

1

Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights (NASDAQ:SPHS)

http://investor.sophirisbio.com/releasedetail.cfm?ReleaseID=998600

Laquo; Previous Release. Next Release ». November 9, 2016. Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights. VANCOUVER, British Columbia. Nov 9, 2016. The "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three and nine months ended. September 30, 2016. August 26, 2016. During the third quarter of 2016, the Company received proceeds of. We had cash, c...

2

Sophiris Bio Inc. - Board of Directors

http://investor.sophirisbio.com/directors.cfm

Prostate cancer program overview. Events & presentations. Dr Lars Ekman /. Member of the Audit Committee. Member of the Governance and Nomination Committee. Randall E. Woods /. Chief Executive Officer and President. Mr Woods has been our Chief Executive Officer and President since August 2012 and a member of our board of directors since October 2012 and brings with him more than 40 years of biotech and pharmaceutical leadership experience. Chair of the Governance and Nomination Committee. Chief Operating...

3

Sophiris Bio Inc. - Events & Presentations

http://investor.sophirisbio.com/events.cfm

Prostate cancer program overview. Events & presentations. Download the Sophiris Investor Presentation. Jun 9, 2016. Sophiris Phase 2a Prostate Cancer Data Investor Webcast. May 7, 2016. Topsalysin Phase 3 Data from Positive Plus-1 Study as a Late Breaking Poster during the 111th American Urological Association Annual Meeting. Jan 28, 2016. Sophiris Investor Webcast: Review of Topsalysin Clinical Data. Mar 13, 2017. 29th Annual ROTH Conference. Please sign up for email alert notification. Feb 2, 2017.

4

Sophiris Bio Inc. - News

http://investor.sophirisbio.com/releases.cfm

Prostate cancer program overview. Events & presentations. Sophiris Bio to Present at 29th Annual ROTH Conference. Mar 6, 2017. SAN DIEGO and VANCOUVER, British Columbia, March 6, 2017 /PRNewswire/ - Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview . Jan 30, 2017. Nov 22, 2016.

5

Sophiris Bio Inc. - Management

http://investor.sophirisbio.com/management.cfm

Prostate cancer program overview. Events & presentations. Sophiris is led by a team that has achieved more than twenty drug approvals including several blockbusters. Randall E Woods /. Dr Allison Hulme /. Chief Operating Officer and Head of Research and Development. Peter T. Slover /. Corporate Governance and Certificates.

UPGRADE TO PREMIUM TO VIEW 8 MORE

TOTAL PAGES IN THIS WEBSITE

13

LINKS TO THIS WEBSITE

sophirisbio.com

Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights | Sophiris

http://www.sophirisbio.com/2014/03/sophiris-bio-reports-fourth-quarter-and-full-year-2013-financial-results-and-key-operational-highlights

Prostate cancer program overview. Events & presentations. Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights. On July 16, 2013 , the Company received a formal waiver from the Food and Drug Administration that the Company will not be required to complete a separate thorough QT study as part of our clinical development plan. During the first quarter of 2013, the Company recognized revenue of $5.0 million associated with a non-refundable milestone pay...

sophirisbio.com

PRX302 | Sophiris

http://www.sophirisbio.com/post/services/prx-302

Prostate cancer program overview. Events & presentations. Learn more about PRX302 and BPH. Learn more about PRX302 and localized prostate cancer. A Highly Targeted Treatment. The mechanism of action is shown in the figure below.

sophirisbio.com

BPH Program Overview | Sophiris

http://www.sophirisbio.com/bph-program-overview

Prostate cancer program overview. Events & presentations. Benign prostatic hyperplasia (BPH or enlarged prostate) is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. Despite available pharmaceutical treatments and surgical options, no single solution provides quick, long-term relief of symptoms without unwanted side effects. Trouble starting and stopping urination. Frequent and irregular needs to urinate, particularly in the night while sleeping.

sophirisbio.com

About Sophiris Bio Inc. Treatment, Prostate Diseases, Benign Prostatic Hyperplasia, Enlarged Prostate Cancer, Transrectal

http://www.sophirisbio.com/about

Prostate cancer program overview. Events & presentations. 1258 Prospect Street,. La Jolla, CA 92037 USA.

sophirisbio.com

PRX302 | Sophiris

http://www.sophirisbio.com/prx-302

Prostate cancer program overview. Events & presentations. Learn more about PRX302 and BPH. Learn more about PRX302 and localized prostate cancer. A Highly Targeted Treatment. The mechanism of action is shown in the figure below.

sophirisbio.com

Publications | Sophiris

http://www.sophirisbio.com/category/publications

Prostate cancer program overview. Events & presentations. Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302. May 14, 2012. By Sophiris Bio News Release. Article published on November 24, 2011. Samuel Denmeade et al. Background: PRX302 is a prostate specific antigen (PSA) activated pore-forming protein toxin under development as a targeted approach for improving lowerurinary tract symptoms (LUTS) caused by. May 7, 2016. By Sophiris Bio News Release. May 6, 2016.

sophirisbio.com

Overview | Sophiris

http://www.sophirisbio.com/clinical_trials

Prostate cancer program overview. Events & presentations. Pts treated with PRX302. IIa Completed (approximately 18 patients). Open label, Phase 2a study, evaluating the safety and tolerability of targeted intraprostatic administration of PRX302 to treat men with histologically proven, clinically significant, localized, low to intermediate risk prostate cancer. III Completed (479 patients). Randomized, double-blind, placebo-controlled, transperineal treatment of PRX302. PLUS-1 phase III trial. The transpe...

sophirisbio.com

About Sophiris Bio Inc. Treatment, Prostate Diseases, Benign Prostatic Hyperplasia, Enlarged Prostate Cancer, Transrectal

http://www.sophirisbio.com/post/services/about-sophiris

Prostate cancer program overview. Events & presentations. 1258 Prospect Street,. La Jolla, CA 92037 USA.

sophirisbio.com

Prostate Cancer Program Overview | Sophiris

http://www.sophirisbio.com/prostate-cancer

Prostate cancer program overview. Events & presentations. Prostate cancer program overview. Background on Localized Low to Intermediate Risk Prostate Cancer. PRX302 for the Targeted Treatment of Localized Low to Intermediate Risk Prostate Cancer. Therefore, PRX302 has the potential to provide a focal targeted therapy for the ablation of localized prostate cancer while potentially avoiding many of the complications and side effects associated with whole gland radical treatments.

UPGRADE TO PREMIUM TO VIEW 36 MORE

TOTAL LINKS TO THIS WEBSITE

45

SOCIAL ENGAGEMENT

share.php

OTHER SITES

investor.softpressmedia.com

Investor Daily : January 16th 2009, Page 1

Error Page cannot be displayed. Please contact your service provider for more details. (18).

investor.sonabank.com

Investor Relations - Southern National Bancorp

Southern National Bancorp of Virginia, Inc. Is the holding company for Sonabank, a state chartered bank. We opened Sonabank? Day High: 11.68. Day Low: 11.45. 4:00 PM ET on. Aug 7, 2015. Delayed 20 min., by eSignal. Jul 23, 2015. Southern National Bancorp of Virginia Inc. Reports Record Earnings of $2.5 Million for the Second Quarter and $4.5 Million for the First Half of 2015, Increases of 39.2% and 30.9%, Respectively, and Strong Loan Growth for the Third Consecutive Quarter. Apr 23, 2015.

investor.sonomaplantworks.com

Investor

Our website works best with Javascripts enabled! Welcome to the SPW Investor Center. Sonoma Plant Works’ goal is to be the largest worldwide provider of retail and wholesale garden solutions. We deliver experience based horticultural education and innovative product lines which further our customer’s garden cultivation through an efficient distribution system delivering the best consumer experience. You are required to login to view this page. 93 S Jackson St. #68221.

investor.sonosite.com

Portable, Point-of-Care Ultrasound | SonoSite

Contact us by Email. Or call 1.877.290.4911. Conferences and Society Meetings. From Skeptic To Believer. Ultrasound Guided Peripheral IV's. 97% First-Pass Success For CVC Placement. Score Zero CLABSI in ICU. Preventative Screenings Impact Lives. Transforming a health system. Videos: MSK Ultrasound Tech. For Dealers and Support Staff. Learn how to improve clinical. Outcomes while reducing costs. Remote Healthcare: 6 Episode Series. Remote Healthcare: 6 Episode Series. DOWNLOAD THE NEW SONOACCESS. Pneumoth...

investor.sophiris.com

Sophiris Bio Inc. - Investor Relations

Prostate cancer program overview. Events & presentations. 08/17/15 4:00 PM ET. Pricing provided by eSignal. Sophiris Bio Reports Second Quarter Financial Results. Aug 13, 2015. Sophiris Bio to Present at the LD Micro Invitational Conference. May 27, 2015. Download the Sophiris Investor Presentation. LD Micro Invitational Conference. Jun 2, 2015 at 11:30 AM PT.

investor.sophirisbio.com

Sophiris Bio Inc. - Investor Relations

Prostate cancer program overview. Events & presentations. 01/12/17 4:00 PM ET. Pricing provided by eSignal. Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference. Nov 22, 2016. Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights. Nov 9, 2016. Download the Sophiris Investor Presentation. 28th Annual Piper Jaffray Healthcare Conference. Nov 30, 2016 at 9:30 AM ET. 2016 BIO Investor Forum. Oct 18, 2016 at 10:30 AM PT.

investor.soundcb.com

Sound Community Bank - Seattle, WA - Investor Relations

Lost or Stolen Card. My Gift Card Login. As of August 17, 2015 -. Minimum 20 minute delay. Sound Financial Bancorp Announces Quarterly Dividend of $0.06 Per Share. Sound Financial Bancorp, Inc. Reports 2nd Quarter Net Income of $1.2 Million or $0.48 Per Share. Sound Financial Bancorp, Inc. Announces Completion of Stock Repurchase Program. Sound Financial Bancorp Announces Quarterly Dividend of $0.06 Per Share. Photo Release - Kathleen B. Cook Joins Sound Community Bank Board of Directors. Photo Release -...

investor.sourcefire.com

Q4 Web Site Development

Q4 Web Maintenance Message. This site is currently under development and not yet available for public viewing. For more information on why this site is not available, please contact Q4.

investor.southerncompany.com

Southern Company - Information for Investors - Overview

SEC Filings by Directors and Officers. Stock Quote and Chart. POWR Historic Stock Pricing. April 4, 2017. Learn about our 2016 activities, financial results and achievements. Watch and read about the advancements we’re making. June 17, 2016. Listen to recent earnings calls, view recent presentations and review our latest financial results. May 1, 2014. See who makes up our board of directors and management council. Learn how the company is governed. April 29, 2014. Find historical closing price for POWR.

investor.sparebank1.no

SpareBank 1 Gruppen – Investor relasjoner – Investor Relations – IR - Investor relasjoner

Invitasjon: Resultatpresentasjon – 2. kvartal 2015. SpareBank 1 SMN, SpareBank 1 SR-Bank ASA, SpareBank 1 Nord-Norge, Sparebanken Hedmark og SpareBank 1 Gruppen inviterer til presentasjon av 2. kvartal 2015. Les mer →. God start på året for SpareBank 1 Gruppen. SpareBank 1 Gruppen leverer det nest beste første kvartalsresultatet noen sinne, med et resultat før skatt på MNOK 378 (337). Annualisert egenkapitalavkastning pr 31.03.15 endte på sterke 17,8 % (16,7). Les mer →. Her er årsrapporten for 2014.

investor.spb.ru

�� -��

Pap-For Russia - 2006. CeBIT 2005 10 16. CeBIT 2005 10 16. Wal-Mart, Aldi, Lidl Auchan .